Literature DB >> 11897007

Anti-Gal alpha 1-3Gal IgM and IgG antibody levels in sera of humans and old world non-human primates.

Katsuhito Teranishi1, Rafael Manez, Michel Awwad, David K C Cooper.   

Abstract

Organs transplanted from pig to primate are rejected within minutes or hours by an antibody-dependent, complement-mediated mechanism [hyperacute rejection (HAR)]. Even after depletion of anti-Gal alpha 1-3Gal (Gal) antibody (Ab), for example by extracorporeal immunoadsorption, return of natural Ab is believed to be a major factor in the initiation of acute humoral xenograft rejection. Various non-human primates are used as recipients of pig organs in experimental discordant xenotransplantation (XTx) models. However, anti-Gal IgM and IgG levels in non-human primates may differ from those in humans. Serum levels of anti-Gal IgM and IgG were measured by enzyme-linked immunosorbent assay (ELISA) in humans (n=14), chimpanzees (n=8), baboons (n=214), cynomolgus monkeys (n=29), rhesus monkeys (n=23) and Japanese monkeys (n=6). The mean level of anti-Gal IgM was significantly higher in chimpanzees than in other groups, while in rhesus monkeys it was significantly lower than in other groups, except baboons and Japanese monkeys. The mean human anti-Gal IgG level was higher than in other groups and this difference reached statistical significance except with regard to chimpanzees. The mean anti-Gal IgG level in baboons was significantly lower than that in humans, chimpanzees and cynomolgus monkeys. The measured differences in anti-Gal IgM and IgG levels may affect the kinetics of Ab removal and rate of return in different species, and thus may have relevance for translating work in non-human primate models to the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897007     DOI: 10.1034/j.1399-3089.2002.1o058.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  20 in total

Review 1.  Significance of the evolutionary α1,3-galactosyltransferase (GGTA1) gene inactivation in preventing extinction of apes and old world monkeys.

Authors:  Uri Galili
Journal:  J Mol Evol       Date:  2014-10-15       Impact factor: 2.395

2.  State-of-the-Art Glycomics Technologies in Glycobiotechnology.

Authors:  Alexander Pralow; Samanta Cajic; Kathirvel Alagesan; Daniel Kolarich; Erdmann Rapp
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 3.  α-Gal Nanoparticles in Wound and Burn Healing Acceleration.

Authors:  Uri Galili
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-03-01       Impact factor: 4.730

4.  Anti-gal antibodies in α1,3-galactosyltransferase gene-knockout pigs.

Authors:  Jason Fang; Anneke Walters; Hidetaka Hara; Cassandra Long; Peter Yeh; David Ayares; David K C Cooper; John Bianchi
Journal:  Xenotransplantation       Date:  2012-09-13       Impact factor: 3.907

Review 5.  Immunological Outcomes of Antibody Binding to Glycans Shared between Microorganisms and Mammals.

Authors:  Preeyam Patel; John F Kearney
Journal:  J Immunol       Date:  2016-12-01       Impact factor: 5.422

6.  Immunological and physiological observations in baboons with life-supporting genetically engineered pig kidney grafts.

Authors:  Hayato Iwase; Hidetaka Hara; Mohamed Ezzelarab; Tao Li; Zhongqiang Zhang; Bingsi Gao; Hong Liu; Cassandra Long; Yi Wang; Amy Cassano; Edwin Klein; Carol Phelps; David Ayares; Abhinav Humar; Martin Wijkstrom; David K C Cooper
Journal:  Xenotransplantation       Date:  2017-03-17       Impact factor: 3.907

7.  Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studies.

Authors:  G L Palmisano; P L Tazzari; E Cozzi; A Bolognesi; L Polito; M Seveso; E Ancona; F Ricci; R Conte; F Stirpe; G B Ferrara; M P Pistillo
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

8.  Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma.

Authors:  Mark R Albertini; Erik A Ranheim; Cindy L Zuleger; Paul M Sondel; Jacquelyn A Hank; Alan Bridges; Michael A Newton; Thomas McFarland; Jennifer Collins; Erin Clements; Mary Beth Henry; Heather B Neuman; Sharon Weber; Giles Whalen; Uri Galili
Journal:  Cancer Immunol Immunother       Date:  2016-05-20       Impact factor: 6.968

Review 9.  Modifying the sugar icing on the transplantation cake.

Authors:  David K C Cooper
Journal:  Glycobiology       Date:  2016-03-01       Impact factor: 4.313

Review 10.  Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits.

Authors:  Uri Galili
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.